FDA greenlights Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia vera

The U.S. Food and Drug Administration has granted approval to rusfertide, a therapy developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics.

The drug, to be marketed under the name Mimrylo, is indicated for the treatment of polycythemia vera, a rare blood disorder characterized by excessive red blood cell production.

This marks the first FDA-approved therapy specifically targeting this condition, offering a new option for patients and potentially expanding the companies' portfolios in hematology.